New cancer clinical trial: Daratumumab and Ibrutinib in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia

Published on: February 27, 2018 at 12:00PM
Condition:   Chronic Lymphocytic Leukemia
Interventions:   Biological: Daratumumab;   Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
Sponsors:   Jennifer Woyach;   National Cancer Institute (NCI)
Not yet recruiting
http://ift.tt/2HOWV0K